United Therapeutics Corporation (UTHR) Return on Equity (ROE): 21.82%
Is United Therapeutics Corporation’s return on equity (ROE) high or low?
United Therapeutics Corporation's return on equity (ROE) of 21.82% is 36% above its 5-year average of 16.03%, near the high end of its 5-year range (12.02%–21.82%).
As of Saturday, June 13, 2026. 16.81% above its 12-month average of 18.68%.
UTHR Return on Equity (ROE) Chart
UTHR Average Return on Equity (ROE) Chart
UTHR Current vs Average Return on Equity (ROE) Chart
UTHR Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
21.82%
RETURN ON EQUITY (ROE) AVG TTM
18.68%
RETURN ON EQUITY (ROE) AVG 3Y
17.25%
RETURN ON EQUITY (ROE) AVG 5Y
16.03%
RETURN ON EQUITY (ROE) AVG 10Y
19.32%
RETURN ON EQUITY (ROE) AVG 15Y
19.72%
RETURN ON EQUITY (ROE) AVG 20Y
17.93%
CURRENT VS TTM AVG
+16.81%
CURRENT VS 3Y AVG
+26.53%
CURRENT VS 5Y AVG
+36.15%
CURRENT VS 10Y AVG
+12.96%
CURRENT VS 15Y AVG
+10.66%
CURRENT VS 20Y AVG
+21.70%
UTHR Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 21.82% | 18.68% | 17.25% | 16.03% |
| Waters Corporation (WAT) | $23.17B | 2.94% | 29.98% | 64.02% | 111.55% |
| BioNTech SE (BNTX) | $22.90B | -6.79% | -4.55% | 10.63% | 21.70% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Labcorp Holdings Inc. (LH) | $21.83B | 10.79% | 9.71% | 9.35% | 12.84% |
| Veeva Systems Inc. (VEEV) | $25.92B | 12.89% | 12.42% | 12.32% | 13.45% |
| Moderna, Inc. (MRNA) | $19.80B | -43.12% | -32.64% | -13.90% | 0.25% |
| DexCom, Inc. (DXCM) | $29.08B | 31.47% | 28.93% | 25.01% | 22.95% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Biogen Inc. (BIIB) | $29.53B | 7.36% | 8.42% | 11.86% | 16.52% |
Return Analysis
ROE
21.8%
ROA
19.2%
United Therapeutics Corporation Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The return on equity (ROE) for UTHR stock is 21.82%.
- Is United Therapeutics Corporation's return on equity (ROE) high or low?
- United Therapeutics Corporation's return on equity (ROE) of 21.82% is 36% above its 5-year average of 16.03%, near the high end of its 5-year range (12.02%–21.82%).
- What is the TTM average return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The TTM average return on equity (ROE) for UTHR stock is 18.68%.
- What is the 3Y average return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The 3Y average return on equity (ROE) for UTHR stock is 17.25%.
- What is the 5Y average return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The 5Y average return on equity (ROE) for UTHR stock is 16.03%.
- What is the 10Y average return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The 10Y average return on equity (ROE) for UTHR stock is 19.32%.
- What is the 15Y average return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The 15Y average return on equity (ROE) for UTHR stock is 19.72%.
- What is the 20Y average return on equity (ROE) for United Therapeutics Corporation (UTHR)?
- The 20Y average return on equity (ROE) for UTHR stock is 17.93%.
United Therapeutics Corporation Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 18.81% |
| 2024-12-31 | 18.55% |
| 2023-12-31 | 16.46% |
| 2022-12-31 | 15.16% |
| 2021-12-31 | 12.02% |
| 2020-12-31 | 15.16% |
| 2019-12-31 | -3.76% |
| 2018-12-31 | 21.13% |
| 2017-12-31 | 19.88% |
| 2016-12-31 | 38.33% |
| 2015-12-31 | 40.74% |
| 2014-12-31 | 26.87% |
| 2013-12-31 | 13.38% |
| 2012-12-31 | 27.81% |
| 2011-12-31 | 22.97% |
| 2010-12-31 | 11.98% |
| 2009-12-31 | 2.98% |
| 2008-12-31 | -8.43% |
| 2007-12-31 | 6.71% |
| 2006-12-31 | 36.15% |
| 2005-12-31 | 23.63% |
| 2004-12-31 | 8.06% |
| 2003-12-31 | -5.94% |
| 2002-12-31 | -13.78% |
| 2001-12-31 | -18.99% |
| 2000-12-31 | -32.21% |
| 1999-12-31 | -62.50% |
| 1998-12-31 | -76.65% |
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt